FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute
AdComNegative
AI Analysis
Summary
Capricor's Phase 3 cell therapy for DMD was not recommended by an FDA Advisory Committee, with panelists criticizing the study data as fragile despite the company's assertion of effectiveness.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA Advisory Committee did not support the cell therapy; panel members characterized data as fragile
Importance:8/10
Sentiment:
-0.80
FDAcell therapyDMDAdComclinical dataregulatory setback
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 30, 2026 11:01 AM